Last reviewed · How we verify
GSK Biologicals' trivalent influenza vaccine — Competitive Intelligence Brief
phase 1
Biologic
Live · refreshed every 30 min
Target snapshot
GSK Biologicals' trivalent influenza vaccine (GSK Biologicals' trivalent influenza vaccine) — GlaxoSmithKline.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| GSK Biologicals' trivalent influenza vaccine TARGET | GSK Biologicals' trivalent influenza vaccine | GlaxoSmithKline | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- GSK Biologicals' trivalent influenza vaccine CI watch — RSS
- GSK Biologicals' trivalent influenza vaccine CI watch — Atom
- GSK Biologicals' trivalent influenza vaccine CI watch — JSON
- GSK Biologicals' trivalent influenza vaccine alone — RSS
Cite this brief
Drug Landscape (2026). GSK Biologicals' trivalent influenza vaccine — Competitive Intelligence Brief. https://druglandscape.com/ci/gsk-biologicals-trivalent-influenza-vaccine. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab